Afasci, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.afasci.com
Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- AlcoholAlcohol Use Disorders
- Interventions
- Drug: AFA-281 is a small molecule, orally availableOther: Alcohol (Ethanol)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 20
- Registration Number
- NCT06719908
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
Phase 2
Not yet recruiting
- Conditions
- Alcohol AbuseAlcohol Abuse/addictionAnxietyPain ThresholdDepression DisordersSleep Disorder
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 36
- Registration Number
- NCT06710431
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 408
- Registration Number
- NCT06649747
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 58
- Registration Number
- NCT05547503
- Locations
- 🇺🇸
CenExcel CNS, Los Alamitos, California, United States
News
No news found